Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the GORE® Drug-Coated PTA Balloon Catheter (GORE® DCB Catheter)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PAD patients with Rutherford Class 2 - 4~* De novo or restenotic lesions, including total occlusions of the SFA/PA~* 1 lesion which may include one or more regions of luminal narrowing ≥70% with a total combined lesion length between 30 - 150mm and a reference vessel diameter of 4 - 6mm~* 1 patent tibial or peroneal artery~Exclusion Criteria:~* Surgical or endovascular access in the Target limb/vessel within the previous 30 days~* Prior treatment of the Target lesion with PTA within 90 days or any prior treatment with drug-coated balloon~* Prior treatment of the Target vessel with stenting or bypass~* Iliac artery inflow lesions that cannot be successfully treated during the Index procedure~* Acute or subacute thrombus or arterial aneurysm in Target limb~* Severe calcification that renders the Target lesion non-dilatable~* Acute or chronic renal dysfunction (serum creatinine ≥2.5 mg/dL)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Coated Balloon (Type: EXPERIMENTAL): Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).